Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Cubist Pharmaceuticals
With that in mind, let's take a closer look at Cubist's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Lexington, Mass. (1992)|
|Market Cap||$2.4 billion|
|Trailing-12-Month Revenue||$803.1 million|
|Management||CEO Michael Bonney
CFO David McGirr
|Return on Equity (average, past 3 years)||14.1%|
|Cash/Debt||$790.2 million / $462.1 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 95% of the 324 members who have rated Cubist believe the stock will outperform the S&P 500 going forward.
I like to green thumb Cubist on pullbacks, since their consistently strong Cubicin revenues provide substantial downside protection. The company also has a strong internal pipeline which has the potential to generate substantial positive catalysts in the near future. I wasn't impressed with the Adolor acquisition, but under new management Entereg is actually showing some signs of life.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Cubist may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.